These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30666207)

  • 1. Rapamycin: A Bacteria-Derived Immunosuppressant That Has Anti-atherosclerotic Effects and Its Clinical Application.
    Liu Y; Yang F; Zou S; Qu L
    Front Pharmacol; 2018; 9():1520. PubMed ID: 30666207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin in cardiovascular medicine.
    Ruygrok PN; Muller DW; Serruys PW
    Intern Med J; 2003 Mar; 33(3):103-9. PubMed ID: 12603583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus, a promising medical therapy for coronary heart disease?
    Jia L; Hui RT
    Med Hypotheses; 2009 Aug; 73(2):153-5. PubMed ID: 19375241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapamycin inhibits human in stent restenosis vascular smooth muscle cells independently of pRB phosphorylation and p53.
    Rosner D; McCarthy N; Bennett M
    Cardiovasc Res; 2005 Jun; 66(3):601-10. PubMed ID: 15914125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells.
    Ollivier V; Hammal S; Ameziane N; Labro MT; de Prost D
    Thromb Haemost; 2005 Jul; 94(1):46-52. PubMed ID: 16113783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rapamycin: from the laboratory to the treatment of patients' arteries].
    Fuster V
    Rev Esp Cardiol; 2003; 56 Suppl 1():2-6. PubMed ID: 15626356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties.
    Zohlnhöfer D; Nührenberg TG; Neumann FJ; Richter T; May AE; Schmidt R; Denker K; Clauss MA; Schömig A; Baeuerle PA
    Mol Pharmacol; 2004 Apr; 65(4):880-9. PubMed ID: 15044617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
    Guarda E; Marchant E; Fajuri A; Martínez A; Morán S; Mendez M; Uriarte P; Valenzuela E; Lazen R
    Am Heart J; 2004 Aug; 148(2):e9. PubMed ID: 15309012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin: signaling in vascular smooth muscle.
    Marks AR
    Transplant Proc; 2003 May; 35(3 Suppl):231S-233S. PubMed ID: 12742501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin and FTY720 Alleviate Atherosclerosis by Cross Talk of Macrophage Polarization and Autophagy.
    Sun RZ; Fan Y; Liang X; Gong TT; Wang Q; Liu H; Shan ZY; Lei L
    Biomed Res Int; 2018; 2018():1010248. PubMed ID: 30627532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin Attenuates Rapamycin-induced Cell Injury of Vascular Endothelial Cells.
    Guo N; Chen F; Zhou J; Fang Y; Li H; Luo Y; Zhang Y
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):338-46. PubMed ID: 26167809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
    Rodriguez AE; Granada JF; Rodriguez-Alemparte M; Vigo CF; Delgado J; Fernandez-Pereira C; Pocovi A; Rodriguez-Granillo AM; Schulz D; Raizner AE; Palacios I; O'Neill W; Kaluza GL; Stone G;
    J Am Coll Cardiol; 2006 Apr; 47(8):1522-9. PubMed ID: 16630986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective clearance of macrophages in atherosclerotic plaques by autophagy.
    Verheye S; Martinet W; Kockx MM; Knaapen MW; Salu K; Timmermans JP; Ellis JT; Kilpatrick DL; De Meyer GR
    J Am Coll Cardiol; 2007 Feb; 49(6):706-15. PubMed ID: 17291937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells.
    Kim Y; Park JK; Seo JH; Ryu HS; Lim KS; Jeong MH; Kang DH; Kang SW
    Sci Rep; 2018 Nov; 8(1):16551. PubMed ID: 30410117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
    Stojkovic S; Ostojic M; Nedeljkovic M; Stankovic G; Beleslin B; Vukcevic V; Orlic D; Arandjelovic A; Kostic J; Dikic M; Tomasevic M
    Catheter Cardiovasc Interv; 2010 Feb; 75(3):317-25. PubMed ID: 20049961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of miRNA-155 in carotid atherosclerotic plaques of apolipoprotein E knockout (ApoE
    Ma J; Yang S; Ma A; Pan X; Wang H; Li N; Liu S; Wu M
    Int Immunopharmacol; 2017 May; 46():70-74. PubMed ID: 28273556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of restenosis with antioxidants: mechanisms and implications.
    Tardif JC; Grégoire J; L'Allier PL
    Am J Cardiovasc Drugs; 2002; 2(5):323-34. PubMed ID: 14727962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.
    Gallo R; Padurean A; Jayaraman T; Marx S; Roque M; Adelman S; Chesebro J; Fallon J; Fuster V; Marks A; Badimon JJ
    Circulation; 1999 Apr; 99(16):2164-70. PubMed ID: 10217658
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.